Search the Newsreel

UiPath Finishes 18% Over Analyst Forecast; Company Officer Offloads $831,250 in Stock

UiPath (PATH) CAO Hitesh Ramani sells 50,000 shares under 10b5-1 plan

Hitesh Ramani, Chief Accounting Officer of UiPath, sold a total of 50,000 shares of Class A Common Stock under a Rule 10b5-1 trading plan. The sales occurred in two separate transactions: 25,000 shares on August 13, 2026, at $16.50 per share, and another 25,000 …

UiPath Inc (PATH) hits active screen on 9.3% jump and 104.5 million-share turnover

The software-infrastructure stock came in with strong weekly momentum, while today intraday price path shows the move cooling after the open.

UiPath Stock Carries A Market Multiple On Earnings And A Premium On Sales

Compass Pathways PLC (CMPS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Compass Pathways PLC (CMPS), focusing on its support, resistance, indicators, and moving averages. As of the analysis, CMPS closed at $13.450 with a 1.20% gain. The technical indicators present a mixed signal, with some indicating 'Buy' and …

Pathfinder Bancorp (PBHC) swings to $2.7M profit in Q2 2026 on credit loss benefit

Should VA-Backed PIVOT Trial on COMP360 in Veterans Require Action From COMPASS Pathways (CMPS) Investors?

COMPASS Pathways announced a collaboration with the U.S. Department of Veterans Affairs on the PIVOT trial, evaluating COMP360 psilocybin for treatment-resistant depression in veterans, including those with PTSD. This initiative strengthens the clinical narrative for COMP360 and expands its data set within a high-need …

UiPath (PATH) Stock Sinks As Market Gains: Here's Why

In the latest trading session, UiPath (PATH) closed at $15.37, marking a -2.23% move from the previous day. This move lagged the S&P 500's daily gain of 0.26%. Elsewhere, the Dow lost 0.04%, while the tech-heavy Nasdaq added 0.54%. The enterprise automation software developer's …

COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript

COMPASS Pathways reported its Q2 2026 earnings, detailing a net loss of $253.8 million, increased G&A expenses, and $433.3 million in cash and cash equivalents expected to fund operations into 2028. The company is on track to submit the final modules of its New …

CMPS: COMP360 targets a 2027 launch, offering rapid, durable relief for TRD and advancing a PTSD program

COMPASS Pathways' product, COMP360, is aiming for a 2027 launch after a Q4 NDA filing, FDA review, and DEA rescheduling. It promises rapid and lasting relief for treatment-resistant depression with a good safety profile and high payer interest. The company is also advancing a …

LightPath Technologies initiated with Overweight rating at Piper Sandler

[Abstract Flow of Digital Data Streams in Blue Neon Light] asbe * Optical component manufacturer LightPath Technologies (LPTH [https://seekingalpha.com/symbol/LPTH]) was initiated with an Overweight rating and a $15 price target at Piper Sandler as the firm sees significant growth ahead. * “LightPath specializes in …

Pathfinder Bancorp Inc (MARYLAND) (PBHC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Compass Pathways PLC (NASDAQ:CMPS) has received a "Moderate Buy" consensus rating from seventeen brokerages, with an average 12-month price target of $23.36, significantly higher than its current share price of $13.38. While some analysts maintained or raised price targets, HC Wainwright lowered its target …

PATH Shares Dip After-Hours Despite Double Beat In Q4 — Retail Says ‘Block The Noise’

HC Wainwright Cuts Earnings Estimates for Compass Pathways

¿Por qué suben hoy las acciones de UiPath? Próximos resultados de septiembre y niveles de resistencia en foco

COMPASS Pathways (CMPS) insider files Form 144 for 26,000 ADS sale

A COMPASS Pathways plc (CMPS) insider has filed a Form 144 to sell 26,000 American Depositary Shares (ADS) through Fidelity Brokerage Services LLC on August 10, 2026. This proposed sale, with an aggregate market value of $345,799.36, follows a stock option exercise by the …

PATH|UiPath Inc|Price:15.050|Chg%:+1.040

This article provides a detailed overview of UiPath Inc (PATH) stock, including live price, key financial figures, stock performance, and analyst ratings. It highlights the company's business profile as an enterprise automation and AI software provider, along with its ownership structure. The data indicates …

Pathkey.AI Shares Halted Ahead of Capital Raising Announcement

3 Reasons PATH is Risky and 1 Stock to Buy Instead

3 Reasons PATH is Risky and 1 Stock to Buy Instead Although UiPath (currently trading at $13.59 per share) has gained 5.4% over the last six months, it has trailed the S&P 500's 11.7% return during that period. This may have investors wondering how …

UiPath (NYSE:PATH) shares surge 18%, spotlight intensifies ahead of September earnings

COMPASS Pathways (CMPS) Joins VA PIVOT Trial, Is The Stock Still Cheap?

COMPASS Pathways (CMPS) Stock Looks Stretched Following Its 214% One Year Run

COMPASS Pathways (CMPS) has seen a significant 214.4% stock gain over the past year, but its current valuation, particularly its Price-to-Book (P/B) ratio of 21.6x, suggests it may be overvalued compared to the biotech industry average. Despite its strong performance, the company's loss-making profile …

Pathfinder Bancorp Inc (MARYLAND) (PBHC) Stock News Today

This article provides current stock information for Pathfinder Bancorp Inc (MARYLAND) (PBHC), including its stock price, market cap, and a note that more news is coming soon. As of the close on August 7, the stock was trading at $16.50, down 1.87%. The page …

Análise e Previsão das Ações da UiPath Inc (PATH)

Technical Reactions to PBHC Trends in Macro Strategies

This article provides a technical analysis of Pathfinder Bancorp Inc. (NASDAQ: PBHC), highlighting strong near-term sentiment that could influence neutral mid and long-term outlooks. It details AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support …

Palantir Surges 10%, UiPath Rises 7%, C3.ai Gains 5% as Agentic AI Stocks Rally Together

Quick Read Palantir surged 10% and UiPath climbed 7% as the agentic AI cohort re-rates together after lagging Monday's initial Palantir-driven move. Bank of America raised Palantir stock's price target to $255, implying 50% upside, while the IGV ETF's 8% weekly gain confirms broad …

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways is collaborating with the U.S. Department of Veterans Affairs (VA) on a multi-site clinical trial to assess the safety and efficacy of COMP360 psilocybin for treating treatment-resistant depression (TRD) in veterans, including those with co-occurring post-traumatic stress disorder (PTSD). The study, named …

COMPASS Pathways plc SEC Filing (Aug 7, 2026)

This article reports on a Form 144 SEC filing by COMPASS Pathways plc (CMPS) dated August 7, 2026. The filing indicates a proposed sale of 83,771 American Depositary Shares, acquired through a stock option exercise on the same date, with an aggregate market value …

Compass Pathways PLC (CMPS) Stock News Today

Renaissance Technologies LLC Reduces Stock Position in Compass Pathways PLC Sponsored ADR $CMPS

Renaissance Technologies LLC decreased its stake in Compass Pathways PLC by 10.6% in the first quarter of 2026, selling 102,492 shares but still retaining 865,354 shares valued at $4.8 million. Despite this reduction, other institutional investors increased their positions, and analysts generally maintain a …

COMPASS Pathways (NasdaqGS:CMPS) Stock Forecast & Analyst Predictions

COMPASS Pathways (CMPS) is forecast to grow earnings and revenue significantly, with analysts predicting a 56.4% earnings growth rate and 67.5% revenue growth rate annually. The company's lead asset, COMP360 psilocybin treatment, has shown promising Phase 3 trial results for treatment-resistant depression (TRD) and …

ETFs Investing in COMPASS Pathways Plc Sponsored ADR Stocks

This article lists various ETFs that hold COMPASS Pathways Plc Sponsored ADR stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and performance metrics. The list is sorted by market value and aims to make investing in these …